Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Zidovudine: five years later.

G X McLeod1, S M Hammer

  • 1New England Deaconess Hospital, Boston, Massachusetts.

Annals of Internal Medicine
|September 15, 1992
PubMed
Summary
This summary is machine-generated.

Zidovudine was the first effective treatment for human immunodeficiency virus type 1 (HIV-1) infection, reducing mortality and opportunistic infections. While resistance and disease progression remain challenges, zidovudine is a cornerstone of combination antiretroviral therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2010
Same author

Collaborative management of HIV infection in the community: an effort to improve the quality of HIV care.

AIDS care·2004
Same author

Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm.

Nature medicine·2003
Same author

Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy.

The Journal of infectious diseases·2001
Same author

Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.

Annals of internal medicine·2001
Same author

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.

The New England journal of medicine·2001
Same journal

Correction to I.M. Matters News: Sleep medicine for seniors.

Annals of internal medicine·2026
Same journal

Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone : A Target Trial Emulation.

Annals of internal medicine·2026
Same journal

Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same journal

Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same journal

Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.

Annals of internal medicine·2026
Same journal

Grappling with GLP-1 prescribing.

Annals of internal medicine·2026
See all related articles

Area of Science:

  • Pharmacology
  • Virology
  • Clinical Medicine

Background:

  • Zidovudine, a nucleoside analog, was the first approved antiretroviral agent for HIV-1 infection.
  • Early studies demonstrated its efficacy in reducing mortality and opportunistic infections in patients with AIDS and advanced AIDS-related complex.
  • Subsequent research established its role in preventing disease progression in earlier stages of HIV infection.

Purpose of the Study:

  • To review the efficacy and toxicity profile of zidovudine in managing HIV-1 infection.
  • To discuss current recommendations for zidovudine dosing and management of its toxicities.
  • To highlight the limitations of zidovudine monotherapy and the promise of combination therapy.

Main Methods:

  • Review of clinical trials and research efforts evaluating zidovudine's efficacy and safety.

Related Experiment Videos

  • Analysis of data on zidovudine's impact on mortality, opportunistic infections, and disease progression.
  • Examination of toxicity profiles, including anemia and neutropenia, and their management.

    • Main Results:

    • Zidovudine effectively decreased mortality and opportunistic infections in advanced HIV disease.
    • Lower-dose zidovudine therapy (500-600 mg/d) is recommended for all stages of HIV disease, with manageable toxicities.
    • HIV-1 strains resistant to zidovudine have emerged, indicating limitations of monotherapy.

    Conclusions:

    • Zidovudine remains a cornerstone of antiretroviral therapy, despite limitations.
    • Combination therapy with zidovudine and other agents shows promise for improved efficacy, reduced toxicity, and prevention of resistance.
    • Ongoing research focuses on understanding zidovudine resistance and optimizing combination regimens.